
Congress should reform the Government Accountability Office, not gut it
GAO's team of more than 3,500 workers conducts reviews and provides reform recommendations to Congress and federal agencies. Its work routinely improves executive agency operations and informs legislation.
GAO is a rare institution in Washington that reports measurable financial savings. Last year, it estimated that its work yielded $67.5 billion in savings — $76 for every dollar of its $900 million budget. That's why the office has long had backers in both political parties and is widely considered the government's most effective cost-cutting agency.
But now, GAO faces political opposition over its statutory responsibilities. Under the Congressional Review Act, GAO issues legal opinions on federal regulations. In March, GAO responded to a congressional inquiry by issuing a decision that undermined congressional Republicans' plans to repeal Clean Air Act waivers issued by the Biden administration. Congress ignored GAO and voted to revoke the regulations anyway.
This controversy has grown into a broader clash over GAO's relationship with the White House. The Impoundment Control Act requires GAO's comptroller general to review presidential funding delays, issue rulings and potentially sue the executive branch. GAO has already found two violations by the Trump administration in 2025 and is reportedly examining dozens more.
In response, the executive branch has shown a new aggression towards GAO. The Office of Management and Budget has called GAO's oversight 'voluminous, burdensome, and inappropriately invasive,' and said it will only cooperate with GAO's reviews if they 'do not unduly impede OMB's ability to implement the president's agenda.'
But GAO is not actively seeking political conflict — it is simply following the law by issuing these decisions. Congressional Republicans should reform the statutes if they disagree.
Beyond legal disputes, some Republicans on Capitol Hill have concerns about GAO's management. Its union secured a telework agreement allowing most employees to work remotely, while Republicans have pressed for other federal workers to return to the office. Some lawmakers and staff also complain GAO reports offer overly cautious, process-oriented recommendations that lack actionable solutions. GAO has also reported some disappointing results in recent years with 30 percent of their recommendations being ignored by federal agencies.
Following the Department of Government Efficiency's aggressive efforts to streamline federal spending and trim the federal workforce, GAO's approach of year-long reviews and lengthy reports with even handed framing may seem timid and ineffectual.
All these conflicts have come to a head in a recent party-line vote by the House Appropriations Committee to approve a bill that would deeply cut GAO's funding and bar the comptroller general from acting on recent impoundments.
Congressional Republicans are right to think that GAO needs reform. But rather than gutting GAO, Congress should fix it to better serve taxpayers and revise its legal responsibilities.
Congress has already been working to improve GAO's return on investment. A 2019 law required agencies to report on progress implementing GAO recommendations, while 2023 laws asked GAO to estimate potential savings from unheeded guidance. Last year, appropriators directed GAO to add deadlines to new recommendations to promote faster action.
Now is a timely moment for Congress to enact broader reforms. Congress and President Trump are poised to choose the next comptroller general after Gene Dodaro's 15-year term ends in December. Legislation to modernize GAO's role, clarify the comptroller general's legal responsibilities, and streamline and refocus the office's work on the most pressing issues facing the federal government could enhance GAO's value for Congress.
Absent such reforms, GAO's future will depend on its next leader. But steep budget cuts will make that job even more difficult.
Former Comptroller General David Walker, who led GAO from 1998 to 2008, warned that the proposed cut is akin to Congress 'shooting itself in the head.' He urged the House and Senate to protect GAO's budget.
Walker knows firsthand the effect of steep budget cuts on the office. In the 1990s, Congress downsized GAO's staffing by over a third. In response, Walker rebranded the agency, refocused its mission, and introduced return-on-investment reporting to demonstrate the office's value. These reforms restored congressional confidence that has largely lasted until now.
But Congress shouldn't force GAO's next leader to endure a similar rebuilding project. Holding hearings and using legislation to modernize GAO's mission would position the next comptroller general to succeed. Congress needs a proactive and trusted watchdog to navigate the difficult governance challenges ahead.
Dan Lips is a senior fellow with the Foundation for American Innovation.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
8 minutes ago
- Newsweek
List of Trump Allies Who Called for Release of Epstein Files
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump and several of his close allies, including many who are working in his administration, vowed that the so-called Epstein client list would be released by Trump. However, Trump has now said on Truth Social "Let's not waste Time and Energy on Jeffrey Epstein, somebody that nobody cares about," and the Department of Justice (DOJ) led by Attorney General Pam Bondi released a memo saying there is "no credible Epstein blackmailed prominent individuals." The so-called Epstein client list is what some believe is a hidden list of people who were involved in Epstein's alleged sex trafficking operation, which he was awaiting trial over when he died by suicide in New York's Metropolitan Correctional Center in 2019. Epstein conspiracy theorists also doubt that he took his own life, which the FBI under Trump has said is the case. Jeffrey Epstein, left, and Donald Trump, right, pose together at the Mar-a-Lago estate in Palm Beach, Florida, in 1997. Jeffrey Epstein, left, and Donald Trump, right, pose together at the Mar-a-Lago estate in Palm Beach, Florida, in 1997. Davidoff Studios/Getty images Why It Matters The president and DOJ's shift regarding Epstein has led to pushback and anger from MAGA voters and from one member of the Trump administration. What To Know Dan Bongino Bongino, now the deputy director of the FBI, said on his podcast in May 2023: "That Jeffrey Epstein story is a big deal. Please do not let that story go. Keep your eye on it." Although Bongino backed up FBI Director Kash Patel's assertions earlier in 2025 that Epstein took his own life, Bongino is reported to be angry at Bondi and the DOJ for failing to produce the alleged client list, and did not report to work on Friday, per NPR reporting. Kash Patel FBI Director Patel has pushed several times for Epstein's alleged client list. In 2023, prior to being appointed to his current position, he told social media personality Benny Johnson that he could obtain Epstein's list with a subpoena to Congress. During his Senate confirmation hearing he told Senator Marsha Blackburn: "I will do everything if confirmed as FBI director to make sure the American public knows the full weight of what happened." Patel then said in his position as FBI director that after reviewing official material, he came to the conclusion that Epstein took his own life. JD Vance Vice President Vance posted on X (formerly Twitter) in 2021: "Remember when we learned that our wealthiest and most powerful people were connected to a guy who ran a literal child sex trafficking ring? And then that guy died mysteriously in a jail? And now we just don't talk about it." He then asserted on Theo Vonn's podcast during the 2024 election campaign: "We need to release the Epstein list." Remember when we learned that our wealthiest and most powerful people were connected to a guy who ran a literal child sex trafficking ring? And then that guy died mysteriously in a jail? And now we just don't talk about it. — JD Vance (@JDVance) September 4, 2021 He is yet to comment publicly on Trump's refusal to look further into the Epstein case, and the president's assertion on Truth Social that the Biden Administration and other Democratic politicians "created the Epstein Files." Pam Bondi Bondi played a key role in pushing Epstein file disclosure. In February 2025, she publicly announced on Fox News that the Epstein "client list" was "sitting on my desk right now to review," noting this was "a directive by President Donald Trump." However, the documents she released to influencers in February outside of the White House did not contain new information on Epstein. A memo from Bondi's DOJ, reported on by Axios, has now said that there is no client list, and Bondi is under scrutiny for her previous statements. Rep. Anna Paulina Luna (R-FL) On February 25, 2025, Luna publicly pressured Bondi on X, formerly Twitter, to act on the Epstein documents. She revealed that House Oversight Committee leaders had sent letters on February 11 and February 19 seeking the status of "releasing the Epstein files" (among other long-secret records) with no response from the DOJ. Luna also posted to X saying: "Reaching out on X because we can't seem to get a response from the AG... what is the status of the documents? These documents were ordered to be declassified." Luna then posted on X on July 8: "The American people deserve to know truth [re.] Epstein, regardless of who it impacts." The American people deserve to know truth ref. Epstein, regardless of who it impacts. There is plenty of evidence and info not pertaining to CSAM/victims that DOJ leadership can authorize the @FBIDirectorKash and @FBIDDBongino to release. The @FBI cannot release anything without… — Rep. Anna Paulina Luna (@RepLuna) July 8, 2025 Other Trump allies who have called for a more thorough Epstein investigation Rep. Marjorie Taylor Greene Rep. Mike Lee Rep. Lauren Boebert Donald Trump Jr. Rudy Giuliani Rep. Tim Burchett Rep. Mike Collins Alina Habba Lt. Gen. Michael Flynn Laura Loomer What Happens Next The DOJ has said there is no Epstein client list, however MAGA voters have expressed anger and frustration with the administration over this conclusion. Epstein's partner, Ghislaine Maxwell, is currently in prison for 20 years over sex trafficking charges, but has appealed her case to the Supreme Court. The DOJ has until July 14 to respond to this appeal. If you or someone you know needs mental health assistance right now, call the National Suicide Prevention Helpline at 1-800-273-TALK (8255). This is a free, confidential crisis hotline that is available to everyone 24 hours a day, seven days a week. If you are in another country, you can go to to find a helpline near you.
Yahoo
9 minutes ago
- Yahoo
Ascentage Pharma's Novel Cancer Drug Approved in China
Ascentage Pharma Group International (NASDAQ:AAPG) is one of the best young stocks to buy and hold for 5 years. On July 10, Ascentage Pharma announced that China's National Medical Products Administration/NMPA approved its novel Bcl-2 selective inhibitor, called lisaftoclax (APG-2575). It treats adult patients with chronic lymphocytic leukemia/CLL and small lymphocytic lymphoma/SLL, particularly those who have previously received at least one systemic therapy, which includes Bruton's tyrosine kinase (BTK) inhibitors. Lisaftoclax is the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL in China, and the second Bcl-2 inhibitor approved globally. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Lisaftoclax is an orally administered small-molecule drug designed to treat malignancies by selectively blocking the antiapoptotic protein Bcl-2, thereby restoring the normal apoptosis process in cancer cells. Clinical trials have demonstrated its therapeutic potential in various hematologic malignancies and solid tumors, particularly CLL/SLL, both as a monotherapy and in combinations. Ascentage Pharma Group International (NASDAQ:AAPG) is a clinical-stage biotechnology company that develops therapies for cancers, chronic hepatitis B virus, and age-related diseases in Mainland China. While we acknowledge the potential of AAPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Mexico's Peso Becomes an Unlikely Winner in Trump's Trade War
(Bloomberg) -- Betting on Mexico's currency has paid off for investors even amid Donald Trump's trade war. Why Did Cars Get So Hard to See Out Of? How German Cities Are Rethinking Women's Safety — With Taxis Advocates Fear US Agents Are Using 'Wellness Checks' on Children as a Prelude to Arrests The peso is up more than 11% this year, beating all regional peers, even as it dipped Monday following the latest tariff news — a threat of a 30% levy announced over the weekend. It is also one of the best performing in emerging markets. Mexico's high interest rates and President Claudia Sheinbaum's tempered approach toward Trump have helped lure in cash from investors reallocating money away from the US. And after months of repeated delays on the implementation of tariffs, money managers have grown more complacent, with reactions to fresh announcements largely contained as they look past Trump's threats to focus on the medium-term outlook. 'Markets know the drill,' said Marco Oviedo, a senior strategist at XP Investimentos in Sao Paulo. 'The only risk that I see is if the Mexican government fails to deliver something that Trump wants on drug control that might leave tariffs high for longer or negotiations in limbo.' Mexico's strong economic ties to the US have also worked in the peso's favor. Most of the nation's exports to the world's largest economy are protected from the latest levy threat thanks to the USMCA trade deal. Although Mexican officials were taken aback by Trump's latest tariff threat, US Ambassador to Mexico Ronald Johnson said Saturday in Mexico City that Sheinbaum and Trump have a 'wonderful relationship' and no partnership should be easier than between their two countries. The central bank has also kept a cautious approach lowering borrowing costs. After delivering a half-point cut that left the key rate at 8% last month, Governor Victoria Rodriguez embraced the likelihood of smaller reductions going forward in a July 9 speech. That helped the peso inch higher last week, outperforming as developing-world currencies slipped amid the latest barrage of tariff announcements. 'The peso is trading incredibly well in the face of this,' said Eric Fine, portfolio manager for emerging markets debt at Van Eck Associates. 'This reaction has many explanations, but EMFX and interest rates have had a great year despite tariff-dominated news flow.' 'Our Goal Is to Get Their Money': Inside a Firm Charged With Scamming Writers for Millions Trump's Cuts Are Making Federal Data Disappear Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot Trade War? No Problem—If You Run a Trade School 'The Turbulence Is Brutal': Four Shark Tank Businesses on Tariffs ©2025 Bloomberg L.P. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data